

David R Coghill

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8625763/david-r-coghill-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193
papers

10,291
citations

57
h-index

97
g-index

225
ext. papers

13,089
ext. citations

6.1
avg, IF

6.27
L-index

#	Paper	IF	Citations
193	Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. <i>American Journal of Psychiatry</i> , 2013 , 170, 275-89	11.9	697
192	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2016 , 30, 495-553	4.6	468
191	Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2018 , 5, 727-738	23.3	378
190	Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. <i>Lancet, The</i> , 2016 , 388, 881-90	4.0	343
189	European clinical guidelines for hyperkinetic disorder -- first upgrade. <i>European Child and Adolescent Psychiatry</i> , 2004 , 13 Suppl 1, 17-30	5.5	316
188	The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. <i>European Child and Adolescent Psychiatry</i> , 2010 , 19, 83-105	5.5	298
187	ADHD in children and young people: prevalence, care pathways, and service provision. <i>Lancet Psychiatry</i> , 2018 , 5, 175-186	23.3	280
186	Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15, 476-95	5.5	275
185	European guidelines on managing adverse effects of medication for ADHD. <i>European Child and Adolescent Psychiatry</i> , 2011 , 20, 17-37	5.5	244
184	Annual research review: categories versus dimensions in the classification and conceptualisation of child and adolescent mental disorders--implications of recent empirical study. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2012 , 53, 469-89	7.9	200
183	Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2014 , 28, 179-203	4.6	191
182	Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2013 , 54, 227-46	7.9	190
181	The validity, reliability and normative scores of the parent, teacher and self report versions of the Strengths and Difficulties Questionnaire in China. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2008 , 2, 8	6.8	185
180	Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E5154-E5163	11.5	182
179	Molecular genetics of attention-deficit/hyperactivity disorder: an overview. <i>European Child and Adolescent Psychiatry</i> , 2010 , 19, 237-57	5.5	170
178	Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. <i>Biological Psychiatry</i> , 2014 , 76, 603-15	7.9	169
177	Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016 , 55, 444-55	7.2	150

176	Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. <i>British Journal of Psychiatry</i> , 2009 , 194, 273-7	5.4	148
175	A comprehensive assessment of memory, delay aversion, timing, inhibition, decision making and variability in attention deficit hyperactivity disorder: advancing beyond the three-pathway models. <i>Psychological Medicine</i> , 2014 , 44, 1989-2001	6.9	130
174	Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. <i>CNS Drugs</i> , 2008 , 22, 213-37	6.7	127
173	The neuropsychological effects of chronic methylphenidate on drug-naïve boys with attention-deficit/hyperactivity disorder. <i>Biological Psychiatry</i> , 2007 , 62, 954-62	7.9	124
172	Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples. <i>American Journal of Psychiatry</i> , 2019 , 176, 531-542	11.9	120
171	Prenatal Risk Factors and the Etiology of ADHD-Review of Existing Evidence. <i>Current Psychiatry Reports</i> , 2017 , 19, 1	9.1	113
170	Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. <i>Lancet Psychiatry</i> , 2018 , 5, 824-835	23.3	105
169	A longitudinal examination of neuropsychological and clinical functioning in boys with attention deficit hyperactivity disorder (ADHD): improvements in executive functioning do not explain clinical improvement. <i>Psychological Medicine</i> , 2014 , 44, 1087-99	6.9	104
168	Neuropsychological functioning in stimulant-naïve boys with hyperkinetic disorder. <i>Psychological Medicine</i> , 2005 , 35, 1109-20	6.9	96
167	ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group. <i>The Lancet Child and Adolescent Health</i> , 2020 , 4, 412-414	14.5	95
166	Whither causal models in the neuroscience of ADHD?. <i>Developmental Science</i> , 2005 , 8, 105-14	4.5	95
165	Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. <i>CNS Drugs</i> , 2017 , 31, 199-215	6.7	94
164	Practitioner review: Quality of life in child mental health--conceptual challenges and practical choices. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2009 , 50, 544-61	7.9	92
163	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 128, 789-818	9	92
162	European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1208-18	1.2	87
161	Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2008 , 2, 31	6.8	86
160	Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II--broader executive and non-executive domains. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2006 , 47, 1184-94	7.9	83
159	Amphetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. <i>European Child and Adolescent Psychiatry</i> , 2012 , 21, 477-92	5.5	81

158	Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15 Suppl 1, 138-45	5.5	81
157	Annual Research Review: Quality of life and childhood mental and behavioural disorders - a critical review of the research. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2017 , 58, 439-469	7.9	79
156	Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2018 , 59, 932-947	7.9	78
155	Psychosocial risk factors for suicidality in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2020 , 29, 759-776	5.5	76
154	Methylphenidate and the risk of trauma. <i>Pediatrics</i> , 2015 , 135, 40-8	7.4	75
153	Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperkinetic disorder. <i>Psychopharmacology</i> , 2004 , 175, 319-30	4.7	75
152	Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15 Suppl 1, 146-55	5.5	72
151	A comprehensive investigation of memory impairment in attention deficit hyperactivity disorder and oppositional defiant disorder. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2012 , 53, 128-37	7.9	68
150	Avoiding the 'twilight zone' recommendations for the transition of services from adolescence to adulthood for young people with ADHD. <i>BMC Psychiatry</i> , 2011 , 11, 174	4.2	68
149	Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. <i>CNS Drugs</i> , 2013 , 27, 1081-92	6.7	64
148	Association of Risk of Suicide Attempts With Methylphenidate Treatment. <i>JAMA Psychiatry</i> , 2017 , 74, 1048-1055	14.5	64
147	The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. <i>CNS Drugs</i> , 2010 , 24, 843-66	6.7	64
146	Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. <i>Pediatrics</i> , 2008 , 121, e314-20	7.4	64
145	Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. <i>BMJ, The</i> , 2017 , 357, j2350	5.9	62
144	Neuropsychological functioning in depressed adolescent girls. <i>Journal of Affective Disorders</i> , 2008 , 111, 113-8	6.6	60
143	Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. <i>Molecular Psychiatry</i> , 2019 , 24, 390-408	15.1	59
142	Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. <i>BMC Psychiatry</i> , 2013 , 13, 237	4.2	59
141	Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. <i>Lancet Psychiatry, the</i> , 2020 , 7, 581-601	23.3	58

140	Brainstem abnormalities in attention deficit hyperactivity disorder support high accuracy individual diagnostic classification. <i>Human Brain Mapping</i> , 2014 , 35, 5179-89	5.9	58
139	The impact of ADHD on the health and well-being of ADHD children and their siblings. <i>European Child and Adolescent Psychiatry</i> , 2016 , 25, 1217-1231	5.5	57
138	Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents. <i>Molecular Psychiatry</i> , 2019 , 24, 1478-1488	15.1	57
137	A systematic review of the safety of lisdexamfetamine dimesylate. <i>CNS Drugs</i> , 2014 , 28, 497-511	6.7	53
136	Occupational issues of adults with ADHD. <i>BMC Psychiatry</i> , 2013 , 13, 59	4.2	52
135	Subcortical Brain Volume, Regional Cortical Thickness, and Cortical Surface Area Across Disorders: Findings From the ENIGMA ADHD, ASD, and OCD Working Groups. <i>American Journal of Psychiatry</i> , 2020 , 177, 834-843	11.9	50
134	Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15 Suppl 1, 163-71	5.5	50
133	Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009 , 19, 683-90	2.9	49
132	The genetics of attention-deficit/hyperactivity disorder. <i>Expert Review of Neurotherapeutics</i> , 2009 , 9, 1547-65	4.3	49
131	Ability and Disability in Autism Spectrum Disorder: A Systematic Literature Review Employing the International Classification of Functioning, Disability and Health-Children and Youth Version. <i>Autism Research</i> , 2015 , 8, 782-94	5.1	48
130	The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). <i>Child and Adolescent Psychiatry and Mental Health</i> , 2013 , 7, 34	6.8	48
129	Attention-deficit/hyperactivity disorder and Williams syndrome: shared behavioral and neuropsychological profiles. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011 , 33, 147-56	2.1	48
128	Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. <i>CNS Drugs</i> , 2013 , 27, 829-40	6.7	45
127	Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2015 , 9, 52	6.8	45
126	Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward. <i>Evidence-Based Mental Health</i> , 2018 , 21, 173-176	11.1	44
125	Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007 , 46, 701-710 ⁷⁻²	7.2	43
124	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2021 , 78, 47-63	14.5	43
123	Health-related quality of life of children with attention-deficit/hyperactivity disorder versus children with diabetes and healthy controls. <i>European Child and Adolescent Psychiatry</i> , 2016 , 25, 261-71	5.5	41

122	Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. <i>European Child and Adolescent Psychiatry</i> , 2017 , 26, 1283-1307	5.5	40
121	Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Archives of Clinical Neuropsychology</i> , 2006 , 21, 797-807	2.7	37
120	Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15 Suppl 1, 14-14	5.5	37
119	Physical Health, Media Use, and Mental Health in Children and Adolescents With ADHD During the COVID-19 Pandemic in Australia. <i>Journal of Attention Disorders</i> , 2020 , 1087054720978549	3.7	37
118	Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. <i>BMC Psychiatry</i> , 2004 , 4, 28	4.2	36
117	Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014 , 53, 647-657.e1	7.2	35
116	Recommendations for the transition of patients with ADHD from child to adult healthcare services: a consensus statement from the UK adult ADHD network. <i>BMC Psychiatry</i> , 2016 , 16, 301	4.2	33
115	The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. <i>CNS Drugs</i> , 2016 , 30, 603-28	6.7	33
114	Do the diagnostic criteria for ADHD need to change? Comments on the preliminary proposals of the DSM-5 ADHD and Disruptive Behavior Disorders Committee. <i>European Child and Adolescent Psychiatry</i> , 2011 , 20, 75-81	5.5	32
113	A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. <i>CNS Drugs</i> , 2013 , 27, 743-51	6.7	31
112	Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. <i>CNS Drugs</i> , 2014 , 28, 1191-203	6.7	31
111	The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research. <i>CNS Drugs</i> , 2015 , 29, 131-51	6.7	28
110	Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 107, 945-968	9	27
109	A comprehensive scoping review of ability and disability in ADHD using the International Classification of Functioning, Disability and Health-Children and Youth Version (ICF-CY). <i>European Child and Adolescent Psychiatry</i> , 2015 , 24, 859-72	5.5	27
108	Predicting methylphenidate response in attention deficit hyperactivity disorder: a preliminary study. <i>Journal of Psychopharmacology</i> , 2015 , 29, 24-30	4.6	27
107	Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients. <i>Current Pharmaceutical Design</i> , 2010 , 16, 2424-33	3.3	27
106	Osmotic, controlled-release methylphenidate for the treatment of ADHD. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 2119-38	4	26
105	The use of stimulant medications for non-core aspects of ADHD and in other disorders. <i>Neuropharmacology</i> , 2014 , 87, 161-72	5.5	25

104	Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe. <i>CNS Drugs</i> , 2017 , 31, 625-638	6.7	25
103	Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial. <i>European Child and Adolescent Psychiatry</i> , 2014 , 23, 61-8	5.5	25
102	Towards an ICF core set for ADHD: a worldwide expert survey on ability and disability. <i>European Child and Adolescent Psychiatry</i> , 2015 , 24, 1509-21	5.5	22
101	Standardised assessment of functioning in ADHD: consensus on the ICF Core Sets for ADHD. <i>European Child and Adolescent Psychiatry</i> , 2018 , 27, 1261-1281	5.5	22
100	Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials. <i>Lancet Psychiatry</i> , 2019 , 6, 528-537	23.3	21
99	Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. <i>CNS Drugs</i> , 2014 , 28, 1059-69	6.7	21
98	Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. <i>BMJ Open</i> , 2017 , 7, e013967	3	20
97	The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication?. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 91, 218-238	9	20
96	A comparison of the clinical effectiveness and cost of specialised individually delivered parent training for preschool attention-deficit/hyperactivity disorder and a generic, group-based programme: a multi-centre, randomised controlled trial of the New Forest Parenting Programme versus Incredible Years. <i>European Child and Adolescent Psychiatry</i> , 2018 , 27, 797-809	5.5	20
95	Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater. <i>Evidence-Based Mental Health</i> , 2016 , 19, 97-99	11.1	20
94	Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis. <i>European Child and Adolescent Psychiatry</i> , 2008 , 17, 245-54	5.5	19
93	Which factors impact on clinician-rated impairment in children with ADHD?. <i>European Child and Adolescent Psychiatry</i> , 2006 , 15 Suppl 1, I30-7	5.5	19
92	Use of stimulants for attention deficit hyperactivity disorder: FOR. <i>BMJ, The</i> , 2004 , 329, 907-8	5.9	19
91	Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 86, 1-11	9	18
90	The MTA at 8. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009 , 48, 1120-1122	7.2	18
89	Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder: The ENIGMA adventure. <i>Human Brain Mapping</i> , 2020 ,	5.9	17
88	Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group. <i>The Lancet Child and Adolescent Health</i> , 2020 , 4, e15	14.5	16
87	Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. <i>Journal of Attention Disorders</i> , 2021 , 25, 1177-1186	3.7	16

86	Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2015 , 8, 383-97	3.8	15
85	Physical exercise in attention deficit hyperactivity disorder - evidence and implications for the treatment of borderline personality disorder. <i>Borderline Personality Disorder and Emotion Dysregulation</i> , 2020 , 7, 1	4.9	14
84	Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate. <i>European Child and Adolescent Psychiatry</i> 2016 , 25, 141-9	5.5	14
83	Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial. <i>Neuropsychiatric Disease and Treatment</i> , 2014 , 10, 2039-47	3.1	14
82	An inventory of European data sources for the long-term safety evaluation of methylphenidate. <i>European Child and Adolescent Psychiatry</i> , 2013 , 22, 605-18	5.5	14
81	Pragmatic measures in paediatric psychopharmacology--are we getting it right?. <i>European Neuropsychopharmacology</i> , 2011 , 21, 571-83	1.2	14
80	Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series study. <i>The Lancet Child and Adolescent Health</i> , 2020 , 4, 435-443	14.5	13
79	Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate. <i>CNS Drugs</i> , 2018 , 32, 85-95	6.7	13
78	Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. <i>European Child and Adolescent Psychiatry</i> , 2014 , 23, 1149-60	5.5	13
77	Measuring methylphenidate response in attention-deficit/hyperactivity disorder: how are laboratory classroom-based measures related to parent ratings?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009 , 19, 691-8	2.9	13
76	Replication of an association of a promoter polymorphism of the dopamine transporter gene and Attention Deficit Hyperactivity Disorder. <i>Neuroscience Letters</i> , 2009 , 462, 179-81	3.3	13
75	Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016 , 26, 537-47	2.9	12
74	Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis. <i>BMJ Open</i> , 2017 , 7, e016608	3	11
73	Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 2555-2565	5.3	11
72	Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 120, 509-525	9	11
71	Services for adults with ADHD: work in progress: Commentary on . . . Specialist adult ADHD clinics in East Anglia. <i>BJPsych Bulletin</i> , 2015 , 39, 140-3	1.2	10
70	OSH Child and Adolescent Psychiatry 2009 ,		10
69	ADHD Symptoms and Quality of Life Across a 12-Month Period in Children With ADHD: A Longitudinal Study. <i>Journal of Attention Disorders</i> , 2019 , 23, 1675-1685	3.7	10

68	Patterns of long-term ADHD medication use in Australian children. <i>Archives of Disease in Childhood</i> , 2020 , 105, 593-597	2.2	10
67	Study protocol for a randomized controlled trial comparing the efficacy of a specialist and a generic parenting programme for the treatment of preschool ADHD. <i>Trials</i> , 2014 , 15, 142	2.8	9
66	Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD. <i>Journal of Attention Disorders</i> , 2019 , 23, 1578-1591	3.7	9
65	Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2018 , 32, 455-467	6.7	9
64	Personalized Medication Response Prediction for Attention-Deficit Hyperactivity Disorder: Learning in the Model Space vs. Learning in the Data Space. <i>Frontiers in Physiology</i> , 2017 , 8, 199	4.6	8
63	Short-term effectiveness of medication and psychosocial intervention in a cohort of newly diagnosed patients with inattention, impulsivity, and hyperactivity problems. <i>Journal of Attention Disorders</i> , 2010 , 14, 147-56	3.7	8
62	Social and Economic Costs of Attention-Deficit/Hyperactivity Disorder Across the Lifespan. <i>Journal of Attention Disorders</i> , 2022 , 26, 72-87	3.7	8
61	Use and predictors of health services among Australian children with mental health problems: A national prospective study. <i>Australian Journal of Psychology</i> , 2020 , 72, 31-40	2.3	8
60	Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). <i>BMC Psychiatry</i> , 2018 , 18, 327	4.2	8
59	An international clinical study of ability and disability in ADHD using the WHO-ICF framework. <i>European Child and Adolescent Psychiatry</i> , 2018 , 27, 1305-1319	5.5	7
58	The provision and nature of ADHD services for children/adolescents in the UK: results from a nationwide survey. <i>Clinical Child Psychology and Psychiatry</i> , 2008 , 13, 287-304	2	7
57	Analysis of structural brain asymmetries in attention-deficit/hyperactivity disorder in 39 datasets. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021 , 62, 1202-1219	7.9	7
56	Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial. <i>BMJ Open</i> , 2018 , 8, e021800	3	7
55	Relationships between behavioral symptoms of non-medicated Chinese children with attention deficit hyperactivity disorder and parenting stress: Comparison of different subtypes and comorbidities. <i>Asia-Pacific Psychiatry</i> , 2016 , 8, 127-35	3.2	6
54	Clinicians' Perceptions of the Australian Paediatric Mental Health Service System: Problems and solutions. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021 , 55, 494-505	2.6	6
53	The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	5
52	A Longitudinal Study of the Relation between Childhood Activities and Psychosocial Adjustment in Early Adolescence. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	5
51	Mental health difficulties across childhood and mental health service use: findings from a longitudinal population-based study. <i>British Journal of Psychiatry</i> , 2020 , 217, 364-369	5.4	5

50	Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age. <i>JAMA Internal Medicine</i> , 2021 , 181, 1332-1340	11.5	5
49	The value of early intervention in creating the new mental health system: Response to Allison et al. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020 , 54, 667-669	2.6	4
48	What Is the Health and Well-Being Burden for Parents Living With a Child With ADHD in the United Kingdom?. <i>Journal of Attention Disorders</i> , 2021 , 25, 1962-1976	3.7	4
47	Examining the Educational Gap for Children with ADHD and Subthreshold ADHD. <i>Journal of Attention Disorders</i> , 2022 , 26, 282-295	3.7	4
46	Developing the Symptoms and Functional Impairment Rating Scale: A Multi-Dimensional ADHD Scale. <i>Psychiatry Investigation</i> , 2018 , 15, 13-23	3.1	4
45	Evaluation of causality between ADHD and Parkinson's disease: Mendelian randomization study. <i>European Neuropsychopharmacology</i> , 2020 , 37, 49-63	1.2	3
44	Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes. <i>Evidence-Based Mental Health</i> , 2007 , 10, 124	11.1	3
43	Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021 , 1-12	6.9	3
42	Characterizing neuroanatomic heterogeneity in people with and without ADHD based on subcortical brain volumes. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021 , 62, 1140-1149 ³	7.9	3
41	A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD). <i>CNS Drugs</i> , 2021 , 35, 1035-1051	6.7	3
40	The European ADHD Guidelines Group replies. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016 , 55, 1092-1093	7.2	2
39	Commentary: We've only just begun: unravelling the underlying genetics of neurodevelopmental disorders--a commentary on Kiser et al. (2015). <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2015 , 56, 296-8	7.9	2
38	Eunethydis: a statement of the ethical principles governing the relationship between the European group for ADHD guidelines, and its members, with commercial for-profit organisations. <i>European Child and Adolescent Psychiatry</i> , 2010 , 19, 737-9	5.5	2
37	The Age of Onset of Attention-Deficit Hyperactivity Disorder 2019 , 217-236		2
36	Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses. <i>European Child and Adolescent Psychiatry</i> , 2021 , 30, 809-821	5.5	2
35	Unbalanced risk-benefit analysis of ADHD drugs - AuthorsReply. <i>Lancet Psychiatry</i> , 2018 , 5, 871-873	23.3	2
34	A systematic review of the persistence of childhood mental health problems into adulthood. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 129, 182-205	9	2
33	A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 283-292	2.2	1

32	Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019 , 29, 285-304	2.9	1
31	Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database. <i>CNS Drugs</i> , 2016 , 30, 317-347	6.7	1
30	Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder. <i>Evidence-Based Mental Health</i> , 2015 , 18, 125	11.1	1
29	Neurofeedback training improves ADHD symptoms more than attention skills training. <i>Evidence-Based Mental Health</i> , 2010 , 13, 21	11.1	1
28	Addressing mental health problems in Australians with cerebral palsy: a need for specialist mental health services. <i>Advances in Mental Health</i> , 1-4	1.2	1
27	Non-stimulant Drug Treatments for Adults with ADHD 2013 , 89-117		1
26	Is minimally adequate treatment really adequate? investigating the effect of mental health treatment on quality of life for children with mental health problems. <i>Journal of Affective Disorders</i> , 2020 , 276, 327-334	6.6	1
25	Pharmacological Approaches in Child and Adolescent Mental Health. <i>Mental Health and Illness Worldwide</i> , 2020 , 543-573	0.1	1
24	Reply to Leon. <i>Evidence-Based Mental Health</i> , 2019 , 22, e2	11.1	1
23	Validity and reliability of the Dundee difficult times of the day scale in Chinese children and adolescents with attention-deficit/hyperactivity disorder. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 33-44	2.1	1
22	A novel school-based approach to screening for attention deficit hyperactivity disorder. <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	1
21	Disentangling ADHD's Presentation-Related Decision-Making-A Meta-Analytic Approach on Predominant Presentations. <i>Frontiers in Psychiatry</i> , 2021 , 12, 519840	5	1
20	Effects of methylphenidate on cognitive functions in boys with attention deficit hyperactivity disorder: Does baseline performance matter?. <i>Journal of Consulting and Clinical Psychology</i> , 2021 , 89, 615-625	6.5	1
19	Suicidality and Self-harm in Adolescents With Attention-Deficit/Hyperactivity Disorder and Subsyndromal ADHD. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021 , 60, 1049-1051	7.2	1.3
18	Pharmacotherapy for Children and Adolescents with Conduct Problems 2011 , 383-404		1
17	A rapid systematic review of attention-deficit/hyperactivity disorder (ADHD) and high order writing: Current findings and implications for intervention.. <i>Research in Developmental Disabilities</i> , 2022 , 123, 104180	2.7	1
16	Post hoc analyses of response rates to pharmacological treatments in children and adolescents with attention-deficit/hyperactivity disorder. <i>Journal of Psychopharmacology</i> , 2020 , 34, 874-882	4.6	0
15	Treatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study. <i>CNS Drugs</i> , 2021 , 35, 769-779	6.7	0

14	Association between methylphenidate and risk of myocardial infarction: A multinational self-controlled case series study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1458-1467	2.6	0
13	Psychotropic Drug Treatment in Childhood and Adolescence 2020 , 525-542		
12	Barriers to medication entitlements after diagnosis of ADHD - AuthorsReply. <i>Lancet Psychiatry</i> , 2018 , 5, 19-20	23.3	
11	Commentary response: Addressing the challenges [response to the commentary of Jarrold and Hall (2012)]. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2012 , 53, 141-142	7.9	
10	Escalas y cuestionarios pragmáticos en psicofarmacología pediátrica: ¿estamos haciendo lo correcto?. <i>Psiquiatria Biologica</i> , 2011 , 18, 105-116	0.2	
9	Stimulant treatments for attention deficit/hyperactivity disorder [how safe are they really?]. <i>Evidence-Based Healthcare and Public Health</i> , 2005 , 9, 83-85		
8	How can the education sector support children's mental health? Views of Australian healthcare clinicians.. <i>PLoS ONE</i> , 2022 , 17, e0261827	3.7	
7	Pharmacological Approaches in Child and Adolescent Mental Health. <i>Mental Health and Illness Worldwide</i> , 2020 , 1-31	0.1	
6	Developmental perspectives on ADHD, treatment implications, and achieving good outcomes 2020 , 211-236		
5	Attention Deficit Hyperactivity Disorder in Males 2021 , 25-42		
4	Can depression be prevented in children and adolescents?. <i>Journal of Paediatrics and Child Health</i> , 2018 , 54, 1386-1388	1.3	
3	The Monash Autism-ADHD genetics and neurodevelopment (MAGNET) project design and methodologies: a dimensional approach to understanding neurobiological and genetic aetiology. <i>Molecular Autism</i> , 2021 , 12, 55	6.5	
2	Psychostimulants: Primary and Secondary Indications 2021 , 1-13		
1	Collaborative and Proactive Solutions compared with usual care to treat irritability in children and adolescents: a pilot randomized controlled trial. <i>Clinical Psychologist</i> , 1-9	1.6	